Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response
about
Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick GetawayNovel microneutralization assay for HCMV using automated data collection and analysis.Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cellsDevelopment and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvantStrain-specific neutralization of human cytomegalovirus isolates by human sera.Intracellular formation and processing of the heterotrimeric gH-gL-gO (gCIII) glycoprotein envelope complex of human cytomegalovirus.Cytomegalovirus vaccine developmentAntigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B.Quantitative temporal viromics: an approach to investigate host-pathogen interactionCharacterization of a panel of insertion mutants in human cytomegalovirus glycoprotein B.Human cytomegalovirus pp28 (UL99) localizes to a cytoplasmic compartment which overlaps the endoplasmic reticulum-golgi-intermediate compartment.Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73).Controlling cytomegalovirus: helping the immune system take the leadA continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination.B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropismStructural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibodyGlycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies.Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantationStrong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challengeEx vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status.A viral regulator of glycoprotein complexes contributes to human cytomegalovirus cell tropism.Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques.Viral Glycoprotein Complex Formation, Essential Function and Immunogenicity in the Guinea Pig Model for CytomegalovirusClinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 TrialHuman cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H.Postoligomerization folding of human cytomegalovirus glycoprotein B: identification of folding intermediates and importance of disulfide bonding.Scanning Mutagenesis of Human Cytomegalovirus Glycoprotein gH/gL.Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex.Characterization of a novel third member of the human cytomegalovirus glycoprotein H-glycoprotein L complex.Strain-specific neutralizing antibody responses against human cytomegalovirus envelope glycoprotein N.Synthetic DNA approach to cytomegalovirus vaccine/immune therapyA Homolog Pentameric Complex Dictates Viral Epithelial Tropism, Pathogenicity and Congenital Infection Rate in Guinea Pig CytomegalovirusThe Cellular Localization of Human Cytomegalovirus Glycoprotein Expression Greatly Influences the Frequency and Functional Phenotype of Specific CD4+ T Cell Responses.Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
P2860
Q26745798-1EF4757B-2229-4550-8742-11F254C2FE29Q31104639-B8D342CA-5E8B-46F8-BE83-7C5335C3B776Q33558361-CDF6A161-658D-4EE0-95F6-6768E7E82756Q33558900-BD533D8E-A48A-4B30-A47C-76E42A6B89E5Q33585524-F33FE898-9ECC-443E-A63A-643F78CD80E7Q33640031-082EF1FC-B726-422F-B426-6CA3BA110C84Q33646932-C32CB682-60F7-4906-89A4-731C3884031FQ33702990-C50CCB9A-EAEF-4C55-8512-8F0F965BC62CQ33707484-EF59784E-2045-40DB-8BA4-19F004A53E04Q33722378-C1EB0C2C-F6AE-48FE-A8B0-5777D985B400Q33793463-5296D5F2-A9E6-4F30-A8E9-616A2F5FEC2DQ33802787-53C4B1A8-9AE8-40A8-869C-D0EEFACFF297Q33813085-C36838F2-EB5F-40A9-87AD-20FBE1005FB6Q33820695-C0784053-85F2-45F7-BFE3-D2D6C925688DQ33935010-EA94A8D6-1867-492D-9485-92358715B274Q33964131-133945FA-1B72-47F9-8D32-FED5F9A92D18Q33996614-1ED0A36F-13F5-401B-91AF-59E3F6A53434Q34212879-8DCB3B55-D31D-400C-956D-14BBB6CD6863Q34317887-ABDB1153-B4F9-48C7-94B4-385CAD50A28CQ34468958-AD1E018D-885D-457E-B076-31A1D0B9FA85Q34809933-B37E9395-39AE-4F22-9C79-74FDB4A49B63Q34970937-75DCC0BC-7FB2-4410-8572-7E6B6C25A7F2Q34975513-5D0019BB-2702-4F4C-BAE6-286C906746BFQ34992770-168F5C9D-E9BD-40D1-841D-B9CFB229CAC5Q35150820-216718D9-B4FE-4D45-89D9-5EBA7F26C4A2Q35378089-7E208A85-EE4D-41AF-BC9D-283D90A71AFCQ35635231-09013A8B-3F9B-419A-A735-FA1535B7CA25Q35743884-66E7A713-0333-4C55-BDEA-26C0401C52A1Q35826628-79888E8D-A602-442D-8AA1-CD7F00612BA9Q35847453-0F59DC05-CE89-43BD-9272-3A1C838F034EQ35850918-D3BC5858-4467-4B51-A1CF-5BDACB02051CQ35866191-3C0A5106-402B-4866-BE80-781115951298Q35881192-8F05CB48-7081-4387-BED5-F911E6AC41B5Q35888421-AC0E0E7F-1E0A-413A-8167-6C693E8D5AB3Q36017790-0525817A-C064-4AF4-975D-EA2D3D6E9E42Q36069582-98D16A63-3C61-4BA6-B4CA-DBCAAF9BB364Q36069719-28924300-EE9D-44A9-ADA2-EB33A6EF668AQ36116754-C07CF289-A82F-4064-93F4-A06B5C6551AEQ36155456-132DC624-ADEA-4D18-8EC7-E7AA4B813FAAQ36385141-19DFDF99-7460-40D4-898A-7A869132A54A
P2860
Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Cell surface expression of hum ...... neutralizing antibody response
@ast
Cell surface expression of hum ...... neutralizing antibody response
@en
type
label
Cell surface expression of hum ...... neutralizing antibody response
@ast
Cell surface expression of hum ...... neutralizing antibody response
@en
prefLabel
Cell surface expression of hum ...... neutralizing antibody response
@ast
Cell surface expression of hum ...... neutralizing antibody response
@en
P2093
P2860
P1433
P1476
Cell surface expression of hum ...... neutralizing antibody response
@en
P2093
E B Stephens
E J Butfiloski
P2860
P304
P407
P577
1990-03-01T00:00:00Z